Gonadotropin-releasing hormone (GnRH) analogues

Phase 1Small molecule

Gonadotropin-releasing hormone (GnRH) analogues is one of 28 small molecule programs targeting Prostate Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerActive, not recruiting

Metastatic Neuroendocrine Prostate CancerActive, not recruiting

Prostate CancerPhase 1

Active, not recruiting

Metastatic Neuroendocrine Prostate CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Novantrone

Pfizer

Preclinical

5 2

Trexall

Alnylam Pharmaceuticals

Preclinical

—3

Viagra

VViatris Specialty LLC

Preclinical

1 4

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 5

Prednisone/prednisolone

Roche

Preclinical

3 6

Triptorelin Pamoate

Ipsen

Preclinical

2 7

Ifex

BBaxter Healthcare Corporation

Preclinical

—8

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

—9

Naropin

FFresenius Kabi Oncology Ltd.

Preclinical

—10

Therapeutic Hydrocortisone

EEastern Cooperative Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Active, not recruiting

Metastatic Neuroendocrine Prostate Cancer

NCT06379217

Q4 2028

Phase 1Recruiting

Prostate Cancer

NCT06531499

Clinical

Trials by Indication[1]

Prostate Cancer1 trial

A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study

Recruiting· Novartis logo

Novartis·Phase 1·NCT06531499·106 enrolled

Metastatic Neuroendocrine Prostate Cancer1 trial

A Phase I, Open-label, Multi-center Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Active, not recruiting· Novartis logo

Novartis·Phase 1·NCT06379217·31 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Gonadotropin-releasing hormone (GnRH) analogues. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gonadotropin-releasing hormone (GnRH) analogues compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gonadotropin-releasing hormone (GnRH) analogues. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Novartis

Gonadotropin-releasing hormone (GnRH) analogues

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2028

Trials by Indication[1]

Prostate Cancer1 trial

Metastatic Neuroendocrine Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News